Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 12, 2025PharmaceuticalsOpen Access

Pharmacogenetics and the Response to Antidepressants in Major Depressive Disorder

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAmanda Gollo BertolloUniversidade Federal de Santa CatarinaRMRicieri MocelinUniversidade Federal da Fronteira SulZIZuleide Maria IgnácioUniversidade Federal da Fronteira Sul

Discussion

Loading...

Member takes

Overview

Review highlights the impact of genetic variations on antidepressant efficacy in different ethnic and sex groups.

Key Points

  • Pharmacogenetic analysis identifies key genetic variants influencing antidepressant response.
  • Variations in CYP2D6 and CYP2C19 significantly impact drug metabolism and tolerability.
  • Ethnic and sex-based disparities affect treatment outcomes and antidepressant efficacy.
  • Integrating genetic insights will optimize personalized treatment strategies for MDD.

Cite This Study

Bertollo et al. (2025) studied this question.

synapsesocial.com/papers/68d44a4031b076d99fa5393fhttps://doi.org/10.3390/ph18091360
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development2017 · 143 citations
  2. 2Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets2016 · 545 citations
  3. 3Role of tumor necrosis factor-alpha in the central nervous system: a focus on autoimmune disorders2023 · 222 citations
  4. 4Genetic Role of BDNF Val66Met and 5-HTTLPR Polymorphisms on Depressive Disorder2014 · 23 citations
  5. 5Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression2023 · 380 citations